<DOC>
	<DOCNO>NCT01181804</DOCNO>
	<brief_summary>This single-dose , randomize , cross-sectional comparison study examine relative safety result blood level profile administration new boceprevir tablet formulation versus current capsule formulation treatment chronic hepatitis C. In Part 1 study participant receive boceprevir tablet capsule fed condition . In Part 2 study new group participant receive boceprevir tablet capsule fast condition .</brief_summary>
	<brief_title>Comparison Safety Resulting Blood Level Profiles After Administration New Boceprevir Tablet Versus Its Current Capsule Formulation Treatment Chronic Hepatitis C ( P06992 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subjects must willing give write informed consent trial able adhere dose visit schedule . Subjects must willing give write informed consent pharmacogenetic testing , able adhere applicable visit schedule . Subjects either gender race age 18 65 year , inclusive , Body Mass Index ( BMI ) 18 32 , inclusive . BMI = weight ( kg ) /height ( ) ^2 . ( Individuals value outside ( indicate low high ) range may enrol clinically acceptable investigator sponsor . ) Subjects ' clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator within allow expanded range supply sponsor . However , subject 's liver function test result ( ie , aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] ) must elevate normal limit Screening Day 1 . No rescreening liver function test allow . Subjects must free clinically significant disease would interfere study evaluation . The Screening 12 lead electrocardiogram [ ECG ] conduction interval must within gender specific normal range ( e.g , ECG QTcB , measure male ≤430 msec QTcB measure females ≤450 msec , PR interval ≤200 msec ) . Vital sign measurement ( take ~3 minute sit position ) must within follow range : ( Individuals value outside range may enrol clinically acceptable investigator sponsor . ) 1. oral body temperature , 35.0°C 37.5°C 2. systolic blood pressure , 90 140 mm Hg 3. diastolic blood pressure , 45 90 mm Hg 4. pulse rate , 40 100 bpm Female subject must : 1. postmenopausal ( defined 12 month menses , age &gt; 40 year folliclestimulating hormone [ FSH ] level &gt; 40 u/mL , serum E2 &lt; 73 pmol/L ) , 2. surgically sterilize least 3 month prior baseline ( eg , document hysterectomy tubal ligation ) , 3. premenopausal unsterilized must use medically accepted method contraception 3 month ( abstain sexual intercourse ) prior screen period , agree use medically accept method contraception trial ( include screen period prior receive trial medication ) 2 month stop trial medication . An acceptable method contraception include one following : i. stable oral , transdermal , injectable , sustainedrelease vaginal hormonal contraceptive regimen without breakthrough uterine bleed 3 month prior Screening ; addition , study use condom and/or spermicide ( marketed country ) . ii . intrauterine device ( insert least 2 month prior Screening visit ) ; addition , study use condom and/or spermicide ( marketed country ) . iii . condom ( male female ) spermicide ( market within country ) , iv . diaphragm cervical cap spermicide ( market within country ) condom ( male ) , Nonvasectomized men must agree use condom spermicide abstain sexual intercourse , trial 1 month stop medication . Female subject pregnant , intend become pregnant ( within 3 month end study ) , breastfeed . Subjects , opinion investigator , able participate optimally study . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . The investigator guide evidence following , discuss sponsor prior enrollment trial : 1. history presence inflammatory bowel disease , ulcer , gastrointestinal rectal bleeding ; 2. history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; 3. history pancreatic injury pancreatitis ; 4. history presence liver disease liver injury ; 5. history presence impair renal function indicate clinically significant elevation creatinine , blood urea nitrogen [ BUN ] /urea , urinary albumin , clinically significant urinary cellular constituent ; 6. history urinary obstruction difficulty void . Subject history infectious disease within 4 week prior drug administration opinion investigator , affect subject 's ability participate trial . Subjects positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus [ HIV ] . Subjects positive screen drug high potential abuse ( Screening period clinical conduct trial ) . Subjects history psychiatric personality disorder opinion investigator sponsor , affect subject 's ability participate trial . Subjects history alcohol drug abuse past 2 year . Subjects donate blood past 60 day . Subjects previously receive boceprevir . Subjects currently participate another clinical study participate clinical study ( e.g. , laboratory clinical evaluation ) within 30 day baseline . Subjects part study staff personnel family member study staff personnel . Subjects demonstrate allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) , opinion investigator sponsor , interfere ability participate trial . Subjects smoke 10 cigarette equivalent tobacco use per day . Subjects history malignancy . Subjects receive prohibited treatment ( prescription non prescription medication except acetaminophen , potent inhibitor inducer cytochrome P3A [ CYP3A4 ] , vitamins herbal ) recently indicate washout period prior Randomization , opinion investigator sponsor , interfere ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>boceprevir</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>SCH 503034</keyword>
</DOC>